{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:15:37Z","timestamp":1787318137025,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T00:00:00Z","timestamp":1501804800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["SAF2016-77784"],"award-info":[{"award-number":["SAF2016-77784"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s00125-017-4388-y","type":"journal-article","created":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T07:46:39Z","timestamp":1501832799000},"page":"2285-2298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes"],"prefix":"10.1007","volume":"60","author":[{"given":"Cristina","family":"Hern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Bogdanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sol\u00e0-Adell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Sampedro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Valeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Gen\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Sim\u00f3-Servat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Garc\u00eda-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Sim\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,4]]},"reference":[{"key":"4388_CR1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.preteyeres.2015.04.003","volume":"48","author":"R Sim\u00f3","year":"2015","unstructured":"Sim\u00f3 R, Hern\u00e1ndez C (2015) Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence. Prog Retin Eye Res 48:160\u2013180","journal-title":"Prog Retin Eye Res"},{"key":"4388_CR2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.preteyeres.2015.08.001","volume":"51","author":"AW Stitt","year":"2016","unstructured":"Stitt AW, Curtis TM, Chen M et al (2016) The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res 51:156\u2013186","journal-title":"Prog Retin Eye Res"},{"key":"4388_CR3","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1136\/bjophthalmol-2012-302005","volume":"96","author":"R Sim\u00f3","year":"2012","unstructured":"Sim\u00f3 R, Hern\u00e1ndez C, European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR) (2012) Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. Br J Ophthalmol 96:1285\u20131290","journal-title":"Br J Ophthalmol"},{"key":"4388_CR4","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1005073","volume":"366","author":"DA Antonetti","year":"2012","unstructured":"Antonetti DA, Klein R, Gardner TW (2012) Diabetic retinopathy. N Engl J Med 366:1227\u20131239","journal-title":"N Engl J Med"},{"key":"4388_CR5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/nyas.12412","volume":"1311","author":"SF Abcouwer","year":"2014","unstructured":"Abcouwer SF, Gardner TW (2014) Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment. Ann N Y Acad Sci 1311:174\u2013190","journal-title":"Ann N Y Acad Sci"},{"key":"4388_CR6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.tem.2013.09.005","volume":"25","author":"R Sim\u00f3","year":"2014","unstructured":"Sim\u00f3 R, Hern\u00e1ndez C, European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR) (2014) Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab 25:23\u201333","journal-title":"Trends Endocrinol Metab"},{"key":"4388_CR7","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.2337\/dc07-0332","volume":"30","author":"E Carrasco","year":"2007","unstructured":"Carrasco E, Hern\u00e1ndez C, Miralles A, Huguet P, Farr\u00e9s J, Sim\u00f3 R (2007) Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration. Diabetes Care 30:2902\u20132908","journal-title":"Diabetes Care"},{"key":"4388_CR8","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1007\/s00125-009-1548-8","volume":"52","author":"M Garcia-Ram\u00edrez","year":"2009","unstructured":"Garcia-Ram\u00edrez M, Hern\u00e1ndez C, Villarroel M et al (2009) Interphotoreceptor retinoid-binding protein (IRBP) is downregulated at early stages of diabetic retinopathy. Diabetologia 52:2633\u20132641","journal-title":"Diabetologia"},{"key":"4388_CR9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db15-0443","volume":"65","author":"C Hern\u00e1ndez","year":"2016","unstructured":"Hern\u00e1ndez C, Bogdanov P, Corraliza L et al (2016) Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes 65:172\u2013187","journal-title":"Diabetes"},{"key":"4388_CR10","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409\u20131439","journal-title":"Physiol Rev"},{"key":"4388_CR11","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.2337\/db12-0926","volume":"62","author":"C Hern\u00e1ndez","year":"2013","unstructured":"Hern\u00e1ndez C, Garc\u00eda-Ram\u00edrez M, Corraliza L et al (2013) Topical administration of somatostatin prevents retinal neurodegeneration in experimental diabetes. Diabetes 62:2569\u20132578","journal-title":"Diabetes"},{"key":"4388_CR12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/B:DOOP.0000036793.44912.45","volume":"108","author":"MF Marmor","year":"2004","unstructured":"Marmor MF, Holder GE, Seeliger MW, Yamamoto S, International Society for Clinical Electrophysiology of Vision (2004) Standard for clinical electroretinography (2004 update). Doc Ophthalmol 108:107\u2013114","journal-title":"Doc Ophthalmol"},{"key":"4388_CR13","doi-asserted-by":"crossref","first-page":"e97302","DOI":"10.1371\/journal.pone.0097302","volume":"9","author":"P Bogdanov","year":"2014","unstructured":"Bogdanov P, Corraliza L, Villena JA et al (2014) The db\/db mouse: a useful model for the study of diabetic retinal neurodegeneration. PLoS One 9:e97302","journal-title":"PLoS One"},{"key":"4388_CR14","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2147\/OPTH.S3967","volume":"2","author":"PJ Anderson","year":"2008","unstructured":"Anderson PJ, Watts H, Hille C et al (2008) Glial and endothelial blood-retinal barrier responses to amyloid-beta in the neural retina of the rat. Clin Ophthalmol 2:801\u2013816","journal-title":"Clin Ophthalmol"},{"key":"4388_CR15","first-page":"789","volume":"42","author":"Q Xu","year":"2001","unstructured":"Xu Q, Qaum T, Adamis AP (2001) Sensitive blood\u2013retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci 42:789\u2013794","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4388_CR16","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1167\/iovs.01-1202","volume":"44","author":"H Xu","year":"2003","unstructured":"Xu H, Forrester JV, Liversidge J, Crane I (2003) Leukocyte trafficking in experimental autoimmune uveitis: breakdown of blood-retinal barrier and upregulation of cellular adhesion molecules. J Invest Ophthalmol Vis Sci 44:226\u2013234","journal-title":"J Invest Ophthalmol Vis Sci"},{"key":"4388_CR17","doi-asserted-by":"crossref","first-page":"e13444","DOI":"10.1371\/journal.pone.0013444","volume":"5","author":"B Anand-Apte","year":"2010","unstructured":"Anand-Apte B, Ebrahem Q, Cutler A et al (2010) Betacellulin induces increased retinal vascular permeability in mice. PLoS One 5:e13444","journal-title":"PLoS One"},{"key":"4388_CR18","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676\u2013682","journal-title":"Nat Methods"},{"key":"4388_CR19","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1515\/CCLM.2011.200","volume":"49","author":"SB Narayan","year":"2011","unstructured":"Narayan SB, Ditewig-Meyers G, Graham KS, Scott R, Bennett MJ (2011) Measurement of plasma amino acids by ultraperformance liquid chromatography. Clin Chem Lab Med 49:1177\u20131185","journal-title":"Clin Chem Lab Med"},{"key":"4388_CR20","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/24884","volume":"396","author":"J Rooij de","year":"1998","unstructured":"de Rooij J, Zwartkruis FJ, Verheijen MH et al (1998) Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396:474\u2013477","journal-title":"Nature"},{"key":"4388_CR21","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1016\/j.febslet.2005.07.080","volume":"579","author":"MR Kooistra","year":"2005","unstructured":"Kooistra MR, Corada M, Dejana E, Bos JL (2005) Epac1 regulates integrity of endothelial cell junctions through VE-cadherin. FEBS Lett 579:4966\u20134972","journal-title":"FEBS Lett"},{"key":"4388_CR22","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.cellsig.2011.03.007","volume":"23","author":"M Breckler","year":"2011","unstructured":"Breckler M, Berthouze M, Laurent AC, Crozatier B, Morel E, Lezoualc\u2019h F (2011) Rap-linked cAMP signaling Epac proteins: compartmentation, functioning and disease implications. Cell Signal 23:1257\u20131266","journal-title":"Cell Signal"},{"key":"4388_CR23","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1002\/jcp.24041","volume":"227","author":"AA Birukova","year":"2012","unstructured":"Birukova AA, Tian Y, Dubrovskyi O et al (2012) VE-cadherin trans-interactions modulate Rac activation and enhancement of lung endothelial barrier by iloprost. J Cell Physiol 227:3405\u20133416","journal-title":"J Cell Physiol"},{"key":"4388_CR24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/1872211308666140130093301","volume":"8","author":"SHS Boddu","year":"2014","unstructured":"Boddu SHS, Gupta H, Patel S (2014) Drug delivery to the back of the eye following topical administration: an update on research and patenting activity. Recent Pat Drug Deliv Formul 8:27\u201336","journal-title":"Recent Pat Drug Deliv Formul"},{"key":"4388_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/db16-1364","volume":"66","author":"R Sim\u00f3","year":"2017","unstructured":"Sim\u00f3 R, Hern\u00e1ndez C (2017) GLP-1 as a target for the treatment of diabetic retinopathy: friend or foe? Diabetes 66:1\u20138","journal-title":"Diabetes"},{"key":"4388_CR26","doi-asserted-by":"crossref","first-page":"e0167853","DOI":"10.1371\/journal.pone.0167853","volume":"11","author":"N Dietrich","year":"2016","unstructured":"Dietrich N, Kolibabka M, Busch S et al (2016) The DPP4 inhibitor linagliptin protects from experimental diabetic retinopathy. PLoS One 11:e0167853","journal-title":"PLoS One"},{"key":"4388_CR27","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.bbadis.2014.06.004","volume":"1842","author":"N Wronkowitz","year":"2014","unstructured":"Wronkowitz N, G\u00f6rgens SW, Romacho T et al (2014) Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2. Biochim Biophys Acta 1842:1613\u20131621","journal-title":"Biochim Biophys Acta"},{"key":"4388_CR28","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1111\/febs.13371","volume":"282","author":"H Zhang","year":"2015","unstructured":"Zhang H, Maqsudi S, Rainczuk A et al (2015) Identification of novel dipeptidyl peptidase 9 substrates by two-dimensional differential in-gel electrophoresis. FEBS J 282:3737\u20133757","journal-title":"FEBS J"},{"key":"4388_CR29","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1463-1326.2011.01548.x","volume":"14","author":"A Gon\u00e7alves","year":"2012","unstructured":"Gon\u00e7alves A, Leal E, Paiva A et al (2012) Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model. Diabetes Obes Metab 14:454\u2013463","journal-title":"Diabetes Obes Metab"},{"key":"4388_CR30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000354116","volume":"50","author":"S Maeda","year":"2013","unstructured":"Maeda S, Yamagishi S, Matsui T et al (2013) Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats. Ophthalmic Res 50:221\u2013226","journal-title":"Ophthalmic Res"},{"key":"4388_CR31","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.bbadis.2014.04.013","volume":"1842","author":"A Gon\u00e7alves","year":"2014","unstructured":"Gon\u00e7alves A, Marques C, Leal E et al (2014) Dipeptidyl peptidase-IV inhibition prevents blood retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats. Biochim Biophys Acta 1842:1454\u20131463","journal-title":"Biochim Biophys Acta"},{"key":"4388_CR32","doi-asserted-by":"crossref","first-page":"29393","DOI":"10.1038\/srep29393","volume":"6","author":"CS Lee","year":"2016","unstructured":"Lee CS, Kim YG, Cho HJ et al (2016) Dipeptidyl peptidase-4 inhibitor increases vascular leakage in retina through VE-cadherin phosphorylation. Sci Rep 6:29393","journal-title":"Sci Rep"},{"key":"4388_CR33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1475-2840-13-19","volume":"13","author":"C Ott","year":"2014","unstructured":"Ott C, Raff U, Schmidt S et al (2014) Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. Cardiovasc Diabetol 13:19","journal-title":"Cardiovasc Diabetol"},{"key":"4388_CR34","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et al (2016) Semaglutide in cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834\u20131844","journal-title":"N Engl J Med"},{"key":"4388_CR35","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00417-008-1004-3","volume":"247","author":"Y Zhang","year":"2009","unstructured":"Zhang Y, Wang Q, Zhang J, Lei X, Xu G-T, Ye W (2009) Protection of exendin-4 analogue in early experimental diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 247:699\u2013706","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4388_CR36","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1167\/iovs.09-4727","volume":"52","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Zhang J, Wang Q et al (2011) Intravitreal injection of exendin-4 analogue protects retinal cells in early diabetic rats. Invest Ophthalmol Vis Sci 52:278\u2013285","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4388_CR37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.peptides.2012.06.006","volume":"37","author":"Z Fu","year":"2012","unstructured":"Fu Z, Kuang HY, Hao M, Gao XY, Liu Y, Shao N (2012) Protection of exenatide for retinal ganglion cells with different glucose concentrations. Peptides 37:25\u201331","journal-title":"Peptides"},{"key":"4388_CR38","first-page":"1557","volume":"10","author":"Y Fan","year":"2014","unstructured":"Fan Y, Liu K, Wang Q, Ruan Y, Zhang Y, Ye W (2014) Exendin-4 protects retinal cells from early diabetes in Goto-Kakizaki rats by increasing the Bcl-2\/Bax and Bcl-xL\/Bax ratios and reducing reactive gliosis. Mol Vis 10:1557\u20131568","journal-title":"Mol Vis"},{"key":"4388_CR39","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.exer.2014.05.004","volume":"127","author":"Y Fan","year":"2014","unstructured":"Fan Y, Liu K, Wang Q, Ruan Y, Ye W, Zhang Y (2014) Exendin-4 alleviates retinal vascular leakage by protecting the blood-retinal barrier and reducing retinal vascular permeability in diabetic Goto-Kakizaki rats. Exp Eye Res 127:104\u2013116","journal-title":"Exp Eye Res"},{"key":"4388_CR40","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.exer.2016.05.002","volume":"151","author":"Y Zeng","year":"2016","unstructured":"Zeng Y, Yang K, Wang F et al (2016) The glucagon like peptide 1 analogue, exendin-4, attenuated oxidative stress-induced retinal cell death in early diabetic rats through promoting Sirt1 and Sirt3 expression. Exp Eye Res 151:203\u2013211","journal-title":"Exp Eye Res"},{"key":"4388_CR41","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/archopht.116.7.874","volume":"116","author":"The Diabetes Control and Complications Trial Research Group","year":"1998","unstructured":"The Diabetes Control and Complications Trial Research Group (1998) Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 116:874\u2013886","journal-title":"Arch Ophthalmol"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-017-4388-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-017-4388-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-017-4388-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T16:12:16Z","timestamp":1659283936000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-017-4388-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,4]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["4388"],"URL":"https:\/\/doi.org\/10.1007\/s00125-017-4388-y","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,4]]}}}